Post Archive by Day

To address malaria outbreaks in Africa, two approved malaria vaccines have been deployed in eight countries, with measurable success.
As 2024 progresses, additional African countries will launch malaria vaccination programs.
Additionally, passive immunization products, which have been tested for years, are now conducting late-stage clinical trials.
These experimental monoclonal antibody therapies offer significant value in protecting children, pregnant women, and immunocompromised individuals from contracting malaria.

As of April 2024, the World Health Organization (WHO) has determined that nearly all circulating SARS-CoV-2 variants reported in publicly available databases are JN.1 derived coronavirus variants.
On April 26, 2024, the WHO stated in a media release that virus evolution is expected to continue from JN.1, and future formulations of COVID-19 vaccines should aim to induce enhanced neutralizing antibody responses to JN.1 and its descendent lineages.
The WHO says the regular review of the available vaccine effectiveness evidence (VE) is critical to assessing future versions.

Physical, psychiatric, and cognitive problems seen in those discharged to long-term acute care hospitals